Michael Edward Derieg

Title: Michael Edward Derieg: Innovator in Tricyclic Benzodiazepines

Introduction

Michael Edward Derieg is a notable inventor based in Caldwell, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of tricyclic benzodiazepines. With a total of 8 patents to his name, Derieg's work has had a substantial impact on the medical community.

Latest Patents

Derieg's latest patents focus on tricyclic benzodiazepine derivatives. These derivatives are characterized by a hydroxylower alkyl substituent in the 1-position and a heterocyclic ring that connects positions 4 and 5 of the benzodiazepine moiety. The heterocyclic ring includes a nitrogen atom at position 4 of the benzodiazepine ring, along with a hetero atom, which can be either oxygen or nitrogen, attached to the carbon atom at the 5-position. The compounds can be synthesized through various methods, including treatment with an epoxide compound in the presence of an acid catalyst. These innovations are particularly useful as sedative, muscle relaxant, and anti-convulsant agents.

Career Highlights

Derieg is currently employed at Hoffmann-La Roche Inc., where he continues to advance his research and development efforts. His work has been instrumental in creating new therapeutic options for patients in need of effective treatments.

Collaborations

Some of his notable coworkers include James Valentine Earley and Rodney I Fryer. Their collaborative efforts have contributed to the success of various projects within the company.

Conclusion

Michael Edward Derieg's innovative work in the field of tricyclic benzodiazepines showcases his dedication to improving medical treatments. His contributions continue to influence the pharmaceutical industry and enhance patient care.